CASI Pharmaceuticals Freezes Juventas Assets Amid Dispute

CASI Pharmaceuticals (CASI) has released an update.

CASI Pharmaceuticals has secured an asset freezing order against Juventas Cell Therapy Ltd. in the Chinese court system, in support of ongoing arbitration related to a commercial dispute over CNCT19. The First Intermediate People’s Court of Tianjin has frozen up to RMB 190 million of Juventas’s assets, with enforcement actions already underway. While the outcome of the arbitration cannot be predicted, CASI is committed to vigorously defending its rights through legal means.

For further insights into CASI stock, check out TipRanks’ Stock Analysis page.